Study on the effect of nursing risk management applied to vaginal flushing during radiotherapyfor cervical cancer patients
护理风险管理应用于宫颈癌患者放疗期间阴道冲洗中的效果研究

摘要

目的 针对护理风险管理应用于宫颈癌患者放疗期间阴道冲洗中的效果展开分析。方法 选取2020年1月-2022年1月期间在我院接受化疗治疗的86例宫颈癌患者作为研究对象，随机抽签分为对照组和研究组，各43例，对照组采用常规阴道冲洗，研究组在常规阴道冲洗的基础上增加护理风险管理，比较两组患者护理前后情绪状态变化情况、阴道不良事件发生率及生活质量（SF-36）评分。结果 护理前，两组患者焦虑自评量表（SAS）、抑郁自评量表（SDS）评分对比差异无统计学意义（P＞0.05），护理后，研究组SAS、SDS评分均低于对照组，差异均有统计学意义（P＜0.05）；研究组SF-36评分高于对照组，阴道炎、阴道粘连、外阴炎、感染发生率低于对照组，差异均有统计学意义（P＜0.05）。结论 将护理风险管理应用于宫颈癌患者放疗期间阴道冲洗中，可帮助患者树立积极的治疗心态，降低阴道不良反应发生风险，提升生活质量，具有临床推广与应用价值。

Abstract

Objective To analyze the effectiveness of nursing risk management applied to vaginal flushing during radiotherapy for cervical cancer patients.
Methods 86 cervical cancer patients who received chemotherapy treatment in our hospital from January 2020 to January 2022 were selected as the study subjects. They were randomly divided into a control group and a study group, with 43 cases in each group. The control group received routine vaginal flushing, while the study group added nursing risk management to the routine vaginal flushing. The emotional state changes, incidence of vaginal adverse events, and quality of life (SF-36) scores of the two groups of patients before and after nursing were compared.
Results Before nursing, there was no statistically significant difference in the scores of the Self Rating Anxiety Scale (SAS) and Self Rating Depression Scale (SDS) between the two groups of patients (P>0.05). After nursing, the SAS and SDS scores of the study group were lower than those of the control group, and the differences were both statistically significant (P<0.05); The SF-36 score of the study group was higher than that of the control group, and the incidence of vaginitis, vaginal adhesions, vulvitis, and infection was lower than that of the control group, with statistical significance (P<0.05).
Conclusion   Applying nursing risk management to vaginal flushing during radiotherapy for cervical cancer patients can help patients establish a positive treatment attitude, reduce the risk of vaginal adverse reactions, improve quality of life, and have clinical promotion and application value.